Oncotarget

Oncotarget Special Collections

 

To see more Oncotarget special collections, please visit: www.oncotarget.com/collections/

 

 

Special Collection on Breast Cancer

Oncotarget | A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis

“Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”


BUFFALO, NY- June 8, 2022 –
A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.”
 

Breast cancer (BC) is the most common type of cancer diagnosed in women. Among female cancer deaths, BC is the second leading cause of death... continue reading >>

Oncotarget: Inhibition of resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

They found that a lengthy treatment... continue reading >>

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1. The missense R273H GOF mtp53 has a mutated central DNA binding domain that renders it unable to bind specifically to DNA, but maintains the... continue reading >>

Oncotarget: BRCA1 mRNA expression in breast and colorectal cancer

Oncotarget published "Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients" which reported that LMNB2 is a chromatin remodeling protein that also plays a role in eukaryotic cell proliferation by organizing the nuclear membrane during mitosis.

High expression of LMNB2 in CRC tumors correlates with worse disease-free cumulative and overall survival, and that knocking out the LMNB2 gene... continue reading >>

Oncotarget: Neutrophils of breast cancer patients and the impairment of T cell responses

Oncotarget published "Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses" which reported that here, the authors observed that LDN were increased in the blood of breast cancer patients, particularly with metastatic disease.

Within the population of non-metastatic patients, LDN were more prevalent in patients with poor response to neoadjuvant chemotherapy than patients with a good response.

The higher ... continue reading >>

Oncotarget: TP53 mutations determined by targeted NGS in breast cancer

Oncotarget published "TP53 mutations determined by targeted NGS in breast cancer: a case-control study" which reported that the purpose of our study is to evaluate the role of TP53 somatic mutations detected via next-generation sequencing as a potential prognostic marker in patients with breast cancer.

23 cases of somatic TP53 mutations and 23 cases of healthy controls were matched on age at diagnosis, menopausal status, histological subtype, histological grade, ki67 expression and disease... continue reading >>

Oncotarget: Clinician's perspective on the 21-gene assay in early breast cancer

Oncotarget published "The clinician's perspective on the 21-gene assay in early breast cancer" which reported that Most patients with early HR and HER2- breast cancer receive a hormone therapy; the clinical question still open is how to identify patients who can really benefit from adjuvant chemotherapy.

The accurate identification of these patients is essential to avoid an over-treatment, increasing the risk of an unnecessary toxicity; on the contrary, the omission of chemotherapy can deprive ... continue reading >>

Oncotarget: Odds of breast cancer by molecular subtype: analysis of the MEND study

Oncotarget published "Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study" which reported that the authors examined the association of high-sensitivity CRP with odds of BC by molecular subtype among Nigerian women.

Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were used to estimate adjusted odds ratios and 95% confidence intervals for the association between hsCRP... continue reading >>

Saudi Arabians: Somatic mutations in breast cancer: new opportunities

Oncotarget published "Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients" which reported that the association between genetic polymorphisms in tumor suppressor genes and the risk of BCa has been studied in many ethnic populations with conflicting conclusions while Arab females and Saudi Arabian studies are still lacking.

The authors screened a cohort of Saudi BCa patients by NGS using a bespoke gene panel to clarify the genetic... continue reading >>

Oncotarget: Radiomics for patients with breast cancer using ultrasound

Oncotarget published "Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound" which reported that the purpose of the study was to investigate the role of pre-treatment quantitative ultrasound -radiomics in predicting recurrence for patients with locally advanced breast cancer.

Patients were determined to have recurrence or no recurrence based on clinical outcomes. With a median follow up of 69 months, 28 patients had disease recurrence.... continue reading >>

Oncotarget: Camptothecin targets WRN protein: in clinical breast cancer

Here is a link to a video interview with Dr. Vihelm A. Bohr about this research on the Oncotarget YouTube Channel

Oncotarget published "Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer" which reported that in the cells treated with CPT, the authors observed distinct effects on WRN compared to other human RecQ helicases.

WRN knockdown cells as well as CPT treated cells became senescent and stained positive for senescence-associated β-galactosidase at a higher ... continue reading >>

Oncotarget: Osteoprotegerin rich tumor microenvironment: implications in breast cancer

Here is a link to a video interview with Dr. Neelam Sharma-Walia about this research on the Oncotarget YouTube Channel

Oncotarget published "Osteoprotegerin rich tumor microenvironment: implications in breast cancer" which reported that Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor -related apoptosis inducing ligand.

Besides having anti-osteoclastic activity, OPG is thought to exert a protective anti-apoptotic action in OPG-expressing tumors by overcoming the... continue reading >>

Oncotarget: LINC00520 is induced by Src, STAT3, and PI3K in breast cancer

Here is a link to a video interview with Dr. Whitney S. Henry about this research on the Oncotarget YouTube Channel

Oncotarget published "LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer" which reported that the authors performed global gene expression profiling of mammary epithelial cells transformed by oncogenic v-Src, and identified a large subset of uncharacterized lncRNAs potentially involved in breast cancer development.

Specifically, their... continue reading >>

Oncotarget: Sequencing interdisciplinary molecular tumor board in breast cancer patients

Oncotarget Volume 11, Issue 35 published "Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer–experiences from a case series" by Walter et, al. which reported that although prognosis of patients with early breast cancer has improved over the last decades, metastatic breast cancer remains incurable.

Despite increasing therapeutic options regarding systemic treatment, predicting efficacy of a targeted drug on a patient level is still challenging.... continue reading >>

Oncotarget: Induction of phenotypic changes in HER2-postive breast cancer cells

The cover for issue 30 of Oncotarget features Figure 4, "RNAseq results demonstrating differences between normal, cancer, and redirected cells," by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not.

Here using in vivo and in vitro models the Oncotarget authors demonstrate the impact... continue reading >>

Oncotarget: Th1 cytokines potentiate apoptosis of breast cancer cells and suppress tumor growth

Volume 11, Issue 30 of Oncotarget reported that previously, the authors showed that anti-estrogen drugs combined with a dendritic cell-based anti-HER-2 vaccine known to induce strong Th1-polarized immunity dramatically improved clinical response rates in patients with HER-2pos/ERpos early breast cancer.

Here, the Oncotarget authors show that the small molecule Akt antagonist MK-2206, when combined with the Th1 cytokines IFN-gamma and TNF-alpha, maximize indicators of apoptotic cell death in a... continue reading >>

Oncotarget: Inhibition of HAS2 and hyaluronic acid production by 1,25-Dihydroxyvitamin D3 in breast cancer

Oncotarget Volume 11, Issue 30 reported that genomic profiling of murine mammary tumor cells with differential VDR expression identified 35 transcripts that were altered by the 1,25D3-VDR complex including Hyaluronan Synthase-2.

Here the Oncotarget authors confirmed that 1,25D3 reduces both HAS2 gene expression and hyaluronic acid synthesis in multiple models of breast cancer.

HAS2 expression and HA production are elevated in immortalized human mammary epithelial cells induced to undergo... continue reading >>

Oncotarget: The Golgi protein TMEM165 controls migration/invasion for carcinoma

The cover for issue 28 of Oncotarget features Figure 5, "TMEM165 expression levels alters N-linked glycosylation," by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry.

The hypothesis is that the TMEM165 protein confers a growth advantage to breast cancer.

The authors created a CRISPR/Cas9 knockout of TMEM165 in the human invasive breast cancer cell... continue reading >>

NFk B drives stemness and resistance to therapy in ER+HER2- breast cancer

Volume 11, Number 19 of @Oncotarget reported that RANK pathway affects the expression of cell cycle regulators and decreases sensitivity to fulvestrant of estrogen receptor-positive /HER2- breast cancer cells, MCF-7 and T47D.

These results suggest that ER+HER2- RANK-positive cells may constitute an important reservoir of slow cycling, therapy-resistance cancer cells; and that RANK pathway activation is deleterious in all ER+HER2- breast cancer cells, independently of RANK levels.

Dr. Sandra... continue reading >>

A distinct pattern of one-carbon metabolism in invasive breast cancer

Volume 11, Issue 18 of @Oncotarget reported that activation of one-carbon metabolism in tumor cells can sustain oncogenesis while contributing to epigenetic changes and metabolic adaptation during tumor progression.

The authors assessed whether increased one-carbon metabolism activity is a metabolic feature of invasive ductal carcinoma.

Their targeted metabolomics analysis showed distinct metabolomics profiles between IDC and adjacent tissue, where IDC displayed a comparative enrichment of... continue reading >>

Proteomic analysis identifies signatures associated w/ survival in breast cancer patients

The cover for issue 17 of @Oncotarget features Figure 8, "Survival probability according to the expression of IGF1R mRNA and an additional gene," by Sinai-Livne, et al.

READ MORE: While this paradigm is based on well-established biological facts, including the potent anti-apoptotic and cell survival capabilities of the receptor, most Phase III clinical trials designed to target the IGF1R led to disappointing results.

Of clinical relevance, these analyses indicate that high IGF1R baseline... continue reading >>

Oncotarget | Risk factors for breast cancer brain metastases: a systematic review

Oncotarget Volume 11, Issue 6 reported that A systematic literature search of EMBASE and MEDLINE was conducted to elucidate the current state of knowledge on known and novel prognostic factors associated with 1) the risk for BCBM and 2) the time to brain metastases (TTBM).

Of these, 69 studies reported risk factors of BCBM, 46 factors associated with the TTBM and twenty studies examined variables for both outcomes.

Young age, estrogen receptor negativity, overexpression of human epidermal... continue reading >>

Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers

While estrogen receptor - + breast cancers express high levels of three anti-apoptotic Bcl-2 family members, pharmacological inhibition of Bcl-2 and/or Bcl-xL fails to induce cell death in ER + breast cancer cell lines, due to rapid and robust Mcl-1 upregulation.

Cells treated with a pharmacological inhibitor of cap-dependent translation, or with the mTORC1 inhibitor RAD001/everolimus, displayed reduced protein levels of Mcl-1 under basal conditions, and failed to upregulate Mcl-1 protein... continue reading >>



Copyright © 2022 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC